Edition:
India

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.63USD
2:29am IST
Change (% chg)

$-0.04 (-2.40%)
Prev Close
$1.67
Open
$1.64
Day's High
$1.68
Day's Low
$1.63
Volume
40,246
Avg. Vol
156,940
52-wk High
$3.74
52-wk Low
$0.71

Latest Key Developments (Source: Significant Developments)

Moleculin Biotech Q3 loss per share $0.14‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Moleculin Biotech Inc : :Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017.Moleculin Biotech Inc - qtrly loss per share $0.14‍​.  Full Article

Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Moleculin Biotech Inc :Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors.Moleculin-Responses to FDA requests for more information regarding physician-sponsored ind for WP1066 as potential treatment for brain tumors submitted​.  Full Article

Moleculin requests for clinical trial authorization to study annamycin
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Moleculin Biotech Inc ::Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland.  Full Article

Moleculin announces strategic collaboration to develop immune stimulation drug
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Moleculin Biotech Inc ::Moleculin announces strategic collaboration to develop immune stimulation drug.Moleculin Biotech - ‍entered into an agreement to collaborate with University of Bergen to expand research on inhibition of brain metastasis by moleculin's pre-clinical drug WP1066​.Moleculin biotech - ‍Moleculin anticipates clinical trial for drug to be ready to begin by end of this year​.Moleculin Biotech - investigational new drug ‍application to study WP1066 ‍in patients with glioblastoma and melanoma has been on hold pending responses to requests from FDA​.Moleculin Biotech - ‍anticipates clinical trial on WP1066 to begin by end of the year. If FDA allows the IND application to proceed based on responses provided​.  Full Article

Moleculin Biotech says working to resubmit IND application for annamycin
Tuesday, 23 May 2017 

May 23 (Reuters) - Moleculin Biotech Inc :Moleculin Biotech issues shareholder update on FDA designation of orphan drug and IND status for annamycin.Moleculin Biotech - working to resubmit IND application for annamycin and to announce co may begin Phase I/II clinical trials by end of July of 2017.Moleculin Biotech - if unable to obtain CMC data on timely basis,will delay resubmitting ind application for annamycin,which will delay clinical trials.  Full Article

Moleculin Biotech says named Walter Klemp CEO
Friday, 14 Oct 2016 

Moleculin Biotech Inc :On October 13, appointed Walter Klemp as the company’s chief executive officer -sec filing.  Full Article

Moleculin appoints new chief financial officer
Monday, 22 Aug 2016 

Moleculin Biotech Inc : Moleculin appoints new chief financial officer . Says Jonathan P. Foster appointed CFO .Says Foster will assume duties of Moleculin's CFO, Louis Ploth, Jr..  Full Article

Moleculin Biotech Q2 loss per share $0.11
Monday, 15 Aug 2016 

Moleculin Biotech Inc :Q2 loss per share $0.11.  Full Article

Moleculin Biotech Inc qtrly loss per share $0.05
Thursday, 16 Jun 2016 

Moleculin Biotech Inc : Qtrly loss per share $0.05 . Moleculin Biotech, Inc. reports financial results for the first quarter ended March 31, 2016 Further company coverage: [MBRX.O].  Full Article

Moleculin Biotech shares debut at $8.99, above IPO price of $6/shr
Thursday, 2 Jun 2016 

: Moleculin Biotech Inc shares open at $8.99 in debut, above IPO price of $6 per share Further company coverage: [MBRX.O] ((Bengaluru Newsroom; +1 646 223 8780;)).  Full Article

BRIEF-Moleculin Biotech Q3 loss per share $0.14‍​

* Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017